INT34585

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1988
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 31
Total Number 31
Disease Relevance 43.54
Pain Relevance 2.47

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (HSD11B1) oxidoreductase activity (HSD11B1) endoplasmic reticulum (HSD11B1)
Anatomy Link Frequency
Lung 3
heart 3
coronary artery 2
plasma 2
fat 2
HSD11B1 (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 82 99.62 Very High Very High Very High
Arthritis 4 99.22 Very High Very High Very High
Restless leg syndrome 5 98.84 Very High Very High Very High
Infliximab 12 98.76 Very High Very High Very High
spinal inflammation 1 98.76 Very High Very High Very High
Inflammation 62 97.74 Very High Very High Very High
antagonist 6 97.12 Very High Very High Very High
Potency 4 94.16 High High
agonist 13 93.92 High High
Bile 202 92.88 High High
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 1656 100.00 Very High Very High Very High
Hypertriglyceridemia 248 100.00 Very High Very High Very High
Breast Cancer 3 100.00 Very High Very High Very High
Cardiovascular Disease 546 99.82 Very High Very High Very High
Rheumatoid Arthritis 84 99.62 Very High Very High Very High
Coronary Artery Disease 406 99.48 Very High Very High Very High
Atherosclerosis 78 99.32 Very High Very High Very High
Seronegative Spondarthritis 2 99.22 Very High Very High Very High
Nicotine Addiction 68 99.14 Very High Very High Very High
Hypertension 85 98.86 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In our study, TAG, TC and LDL-C showed a significant reduction with an increase on HDL-C concentration after a study period of six weeks.
Negative_regulation (reduction) of Positive_regulation (increase) of HDL associated with disorder of lipid metabolism
1) Confidence 0.57 Published 2007 Journal Lipids Health Dis Section Body Doc Link PMC2211748 Disease Relevance 1.25 Pain Relevance 0
9 mg/dl (0.24 mmol/L) increase in HDL-C decreased by the 17% risk of CVD in our non-diabetic men, but not in non-diabetic women.
Negative_regulation (decreased) of Neg (not) Positive_regulation (increase) of HDL associated with diabetes mellitus, cardiovascular disease and disorder of lipid metabolism
2) Confidence 0.42 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2835707 Disease Relevance 3.45 Pain Relevance 0
The reduced atherogenic index in both treatments was mainly due to the decrease in serum total cholesterol level rather than elevation in serum HDL-C level.


Negative_regulation (decrease) of Positive_regulation (elevation) of HDL associated with disorder of lipid metabolism
3) Confidence 0.42 Published 2005 Journal Lipids Health Dis Section Body Doc Link PMC1266394 Disease Relevance 0.87 Pain Relevance 0
Other studies had previously shown that increased levels of large alpha-1 and alpha-2 HDLs decrease the risk of coronary heart disease and protect against progression of coronary atherosclerosis.
Negative_regulation (decrease) of Positive_regulation (increased) of HDL in heart associated with coronary artery disease
4) Confidence 0.42 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2672446 Disease Relevance 1.88 Pain Relevance 0
Hypertension and certain alterations in serum lipoproteins such as a decrease in high density lipoprotein-cholesterol (HDL-C), an increase in low density lipoprotein-cholesterol (LDL-C) and perhaps also elevated triglycerides (Tg), are complementary coronary risk factors.
Negative_regulation (decrease) of Positive_regulation (increase) of HDL associated with hypertriglyceridemia, hypertension and disorder of lipid metabolism
5) Confidence 0.41 Published 1988 Journal Drugs Section Abstract Doc Link 3042351 Disease Relevance 0.58 Pain Relevance 0
The Familial Atherosclerosis Treatment Study (FATS) evaluated 38 men with coronary artery atherosclerosis and a family history of cardiovascular disease treated with colestipol 30 g/day and lovastatin 40 mg/day for 2.5 years, resulting in a 46% decrease in LDL-C and 15% increase in HDL-C levels, which was associated with significant decreased progression and increased regression of atherosclerotic coronary lesions compared with conventional therapy (Brown et al 1990).
Negative_regulation (decrease) of Positive_regulation (increase) of HDL in coronary artery associated with cardiovascular disease, atherosclerosis and disorder of lipid metabolism
6) Confidence 0.41 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291317 Disease Relevance 1.12 Pain Relevance 0
A study involving rabbits demonstrated a reduction in circulating TC and an increase in HDL-C upon virgin olive oil consumption.
Negative_regulation (reduction) of Positive_regulation (increase) of HDL associated with disorder of lipid metabolism
7) Confidence 0.41 Published 2010 Journal International Journal of Molecular Sciences Section Body Doc Link PMC2852848 Disease Relevance 0.91 Pain Relevance 0
The observed changes between the time of referral and discharge from the CRRC were decreases in LDL-C (19.1%), TC (17.9%), TG (40.3%), and TC:HDL (22.8%), as well as an increase in HDL-C (8.9%), which were all statistically significant (p < 0.0001).
Negative_regulation (decreases) of Positive_regulation (increase) of HDL associated with disorder of lipid metabolism
8) Confidence 0.41 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2605345 Disease Relevance 0.65 Pain Relevance 0
Oant et al. showed that in the general Turkish adult population, a 12 mg/dl increase of HDL-C in men, decreased the risk of CHD by 20%, whereas HDL-C did not protect the development of CHD in women [33]; similarly ?
Negative_regulation (decreased) of Positive_regulation (increase) of HDL associated with coronary artery disease and disorder of lipid metabolism
9) Confidence 0.41 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2835707 Disease Relevance 3.33 Pain Relevance 0
A 1 SD increase of HDL-C decreased risk of CVD by 17% in both models in non-diabetic men.
Negative_regulation (decreased) of Positive_regulation (increase) of HDL associated with diabetes mellitus, cardiovascular disease and disorder of lipid metabolism
10) Confidence 0.41 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2835707 Disease Relevance 3.95 Pain Relevance 0
Among non-diabetic men, all lipid measures, except for TG, were independent predictors for CVD; a 1 SD increase in HDL-C however, significantly decreased the risk of CVD, with almost same discriminatory power.
Negative_regulation (decreased) of Positive_regulation (increase) of HDL associated with hypertriglyceridemia, cardiovascular disease, diabetes mellitus and disorder of lipid metabolism
11) Confidence 0.41 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2835707 Disease Relevance 3.63 Pain Relevance 0
A National Heart and Lung Blood Institute study of 116 men and women with CHD treated with cholestyramine 24 g/day for 5 years showed a 26% decrease in LDL-C and an 8% increase in HDL-C, with reduced atherosclerotic progression in coronary artery lesions with stenosis greater than 50% (Brensike et al 1984).
Negative_regulation (decrease) of Positive_regulation (increase) of HDL in Lung associated with pathologic constriction, coronary artery disease, atherosclerosis and disorder of lipid metabolism
12) Confidence 0.41 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291317 Disease Relevance 1.01 Pain Relevance 0.04
Another arm of the FATS study evaluated colestipol 30 g/day and niacin 4 g/day in 36 men with the same entry criteria, also followed for 2.5 years, and found a 32% decrease in LDL-C and a 43% increase in HDL-C levels.
Negative_regulation (decrease) of Positive_regulation (increase) of HDL in arm associated with disorder of lipid metabolism
13) Confidence 0.41 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291317 Disease Relevance 1.06 Pain Relevance 0
In a study conduced by Berne in type 2 diabetic patients, prescription of rosuvastatin (10 mg/day) by 4 weeks decreased significatively LDL-C levels in a mean percentage of 47.6%, TC in 33.6%, TAG in 19.2% and increased HDL-C in 4.4%, and demonstrated more response on lipid profile in comparison with atorvastatin at the same dose [47].
Negative_regulation (decreased) of Positive_regulation (increased) of HDL associated with diabetes mellitus and disorder of lipid metabolism
14) Confidence 0.41 Published 2007 Journal Lipids Health Dis Section Body Doc Link PMC2211748 Disease Relevance 1.00 Pain Relevance 0.04
Part of this protective effect seems to be due to the influence of estrogen therapy on lipoprotein metabolism, i.e. a decrease in LDL cholesterol and an increase in HDL cholesterol.
Negative_regulation (decrease) of Positive_regulation (increase) of HDL associated with disorder of lipid metabolism
15) Confidence 0.41 Published 1995 Journal Horm. Res. Section Abstract Doc Link 7721254 Disease Relevance 1.00 Pain Relevance 0.11
Raloxifene reduces the risk of positive estrogen receptor breast cancer, decreases total cholesterol and LDL cholesterol, increases HDL cholesterol, does not increase the risk of endometrial cancer or cause bleeding and spotting.
Negative_regulation (reduces) of Positive_regulation (increases) of HDL associated with endometriosis (extended), breast cancer, hemorrhage, reprotox - general 1 and disorder of lipid metabolism
16) Confidence 0.41 Published 2001 Journal Med. Sci. Monit. Section Abstract Doc Link 11535963 Disease Relevance 1.11 Pain Relevance 0.19
After eight weeks of administration of cilostazol to patients with IC, walking distances were increased, associated with a 29% decrease in plasma triglycerides and a 13% increase in HDL-C.
Negative_regulation (decrease) of Positive_regulation (increase) of HDL in plasma associated with restless leg syndrome and disorder of lipid metabolism
17) Confidence 0.41 Published 2001 Journal Atherosclerosis Section Abstract Doc Link 11583728 Disease Relevance 0.72 Pain Relevance 0.46
Lovastatin treatment was associated with statistically significant decreases in LDL-C and increases in HDL-C, and chronic long-term treatment with 20-40 mg/day lovastatin was well tolerated in women.
Negative_regulation (decreases) of Positive_regulation (increases) of HDL associated with disorder of lipid metabolism
18) Confidence 0.41 Published 2001 Journal J Womens Health Gend Based Med Section Abstract Doc Link 11788107 Disease Relevance 0.35 Pain Relevance 0
D-003 decreased low-density lipoprotein-cholesterol (LDL-C) (32.8%), total cholesterol (TC) (16.4%) and the TC/high-density lipoprotein-cholesterol (HDL-C) ratio (34.7%), increased HDL-C (30.3%) (p < 0.001) and did not modify triglycerides.
Negative_regulation (decreased) of Neg (not) Positive_regulation (increased) of HDL associated with disorder of lipid metabolism
19) Confidence 0.41 Published 2005 Journal Int J Clin Pharmacol Res Section Abstract Doc Link 16402634 Disease Relevance 0.85 Pain Relevance 0.07
Generally it can be assumed that niacin at a dose of more than 1.5 g/day will decrease LDL-cholesterol, triglycerides and lipoprotein(a) by approximately 20%, while it will increase HDL-cholesterol also by approximately 20% (“rule of 20%”).9,15

Mechanism of action of niacin

Negative_regulation (decrease) of Positive_regulation (increase) of HDL associated with disorder of lipid metabolism
20) Confidence 0.37 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2788595 Disease Relevance 0.37 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox